Table 3.
Multivariate cox proportional hazards regression model to predict progression-free survival from chemotherapy start by FRS2α intensity level
| Variable | Level | Hazard ratio | 95% Hazard ratio confidence limits | Probability > Chi square test | |
|---|---|---|---|---|---|
| Treatment arm | Sorafenib vs. Sorafenib + interferon | 1.915 | 0.850 | 4.314 | 0.1171 |
| ECOG Status | 1 vs. 0 | 4.651 | 1.508 | 14.341 | 0.0075 |
| Anemia | Yes vs. No | 1.831 | 0.628 | 5.342 | 0.2683 |
| FRS2α Intensity | (3 or 4) vs. 1 | 7.318 | 1.531 | 34.971 | 0.0126 |
| 2 vs. 1 | 2.959 | 0.765 | 11.449 | 0.1161 | |
ECOG, Eastern Cooperative Oncology Group; FRS2α, fibroblast growth factor receptor substrate 2 alpha.